Home Biosimilar Antibodies Apoptosis Others Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262)
For research use only. Not for use in humans.

Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262)

Synonyms: AMG 655,TRAIL-R2 mAb

Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) with a Kd of 1 nM and 0.8 nM for the long form and the short form of DR5, respectively. Conatumumab induces apoptosis via caspase activation. MW : 144.96 KD.

Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262)

Quality Control

Batch: Purity: 99% Protein concentration: 8.052mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) with a Kd of 1 nM and 0.8 nM for the long form and the short form of DR5, respectively. Conatumumab induces apoptosis via caspase activation. MW : 144.96 KD.

Product Details

CAS No.  896731-82-1
Molecular Weight 144.96 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06251544 NOT_YET_RECRUITING Breast Cancer; Tumor, Breast; Breast Tumor; Malignant Neoplasm of Breast; Mammary Cancer; Mammary Neoplasm; Mammary Neoplasms, Human; Neoplasm, Breast Baylor College of Medicine 2026-06 PHASE1
NCT01327612 COMPLETED Drug: Modified FOLFOX6 Advanced Solid Tumors; Carcinoid; Colorectal Cancer; Locally Advanced; Lymphoma; Metastatic Cancer; Non-Small Cell Lung Cancer; Sarcoma; Solid Tumors Amgen 2011-03-03 PHASE2
NCT02991196 TERMINATED Drug: DS-8273a + nivolumab Colorectal Neoplasm Daiichi Sankyo 2016-12-01 PHASE1
NCT01940172 COMPLETED Drug: Birinapant|Drug: Conatumumab Relapsed Epithelial Ovarian Cancer; Relapsed Primary Peritoneal Cancer; Relapsed Fallopian Tube Cancer TetraLogic Pharmaceuticals 2013-11 PHASE1
NCT00630786 COMPLETED Drug: Panitumumab|Drug: Conatumumab Colon Cancer; Colorectal Cancer; Rectal Cancer; Metastatic Colorectal Cancer; Oncology Amgen 2008-01 PHASE1; PHASE2
NCT01017822 WITHDRAWN Drug: capecitabine|Drug: gemcitabine hydrochloride Pancreatic Cancer Radiation Therapy Oncology Group PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-03-04)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.